Search results
View the profiles of people named Jennifer Davis. Join Facebook to connect with Jennifer Davis and others you may know. Facebook gives people the power...
Jennifer Davis Chief Executive Officer, Health Care. Jennifer leads P&G’s global Health Care business, which encompasses the company’s Oral Care and Personal Health Care businesses and makes up 14% of P&G’s net sales.
Oct 16, 2023 · Jennifer Davis, 46, was diagnosed with triple-negative breast cancer in 2018, and underwent intense treatment and chemotherapy. In 2021, she opted to receive the first triple-negative...
People also ask
Who is Jenna Davis?
Who is Jennifer Davis?
Who is Jennifer Davies?
Who is Jenny Davis?
Jennifer (“Jenna”) Davis is Professor of Civil and Environmental Engineering and the Higgins-Magid Senior Fellow at the Woods Institute for the Environment, both of Stanford University. She also heads the Stanford Program on Water, Health & Development.
- Overview
- How life changed after diagnosis
- The science behind the vaccine
- Clinical trials are life-saving
- GeneratedCaptionsTabForHeroSec
•A human clinical trial is underway for a breast cancer vaccine.
•Breast cancer survivor Jennifer Davis is the first person to receive the vaccine.
•Researchers hope the vaccine could rid the world of breast cancer in the near future.
What if a vaccine could eliminate breast cancer from the world?
Scientists behind a Cleveland Clinic and Anixa Biosciences clinical trial hope their vaccine may be the one.
“We believe that within 5 years this vaccine will be available for [people] who are breast cancer survivors and worried about recurrence and then 2 to 4 years after that we believe it can be available for all women, including women who have never had cancer, and potentially this vaccine could be an option for every woman in the world,” Amit Kumar, PhD, CEO of Anixa Biosciences, told Healthline.
In February 2018 at 41 years old, Davis discovered a lump on her breast. After several tests, she was diagnosed with TNBC.
TNBC typically grows fast, is more likely to have spread to other areas of the body once it is first detected, and has a higher reoccurrence rate after treatment than other types of breast cancer. Moreover, the survival rates for those with TNBC are generally not as high as they are for those who have other types of breast cancer, reports the American Cancer Society.
“I’m a nurse…but oncology isn’t my specialty and I didn’t know much about triple negative and it’s all over the [internet as the] most lethal form and prognosis is poor, death is high, and the first thing I told [my family when I was diagnosed] is don’t Google triple negative,” Davis told Healthline.
As a resident of Ohio, she decided to get a second opinion from Cleveland Clinic and then received treatment there.
She underwent multiple rounds of chemotherapy followed by a double mastectomy and then 26 rounds of radiation.
“With triple negative, there’s nothing you can take following your treatment to put your mind at ease that you won’t have a recurrence,” said Davis.
The vaccine was in the works for more than 20 years before it reached the human trial phase.
Vincent Tuohy, PhD, a researcher in the Department of Inflammation and Immunity at the Cleveland Clinic invented the vaccine. While he passed away in January 2023, his groundbreaking research continues to carry on.
Tuohy identified that a protein called α-lactalbumin (aLA), which is produced in pregnant and lactating people is often a precursor to cancer.
While aLA is necessary to produce breast milk, when a woman stops lactating, the body stops making the protein.
“The discovery that was key here is that later on in life when women develop breast cancer, those cancer cells are making this protein again even though she’s not lactating,” said Kumar.
Tuohy hypothesized that if a vaccine could train a woman’s immune system to attack the cells making aLA then when those cancer cells arise, the immune system would be ready to destroy the cells before they have a chance to reproduce and become a tumor.
Clinical trials are essential to the progression of treatment for TNBC, said Dr. Francisco Esteva, chief of breast medical oncology at Northwell Lenox Hill Hospital.
“A few years ago, all we had was chemotherapy. Now there’s antibody-drug conjugate (ADCs) that are now used in routine care for these patients,” Esteva told Healthline.
While experimental vaccines for breast cancer have existed for many years, he said so far none have shown improvement in survival rates. However, he has hope that through well-designed, randomized clinical trials that are approved by scientific and ethics committees, patient advocates, the FDA, and government entities, a vaccine will be effective.
“Clinical trials are really important because what we do today as standard of care was only a clinical trial a few years ago,” said Esteva. “For someone who has completed all their treatment and has no additional effective treatments available to them, it’s very important to consider clinical trials.”
Davis knows this too well. She said participating in the trial is rewarding not only in the moment but also because of what it means for the future.
“[It’s amazing] that one day, [breast cancer] could not exist and women won’t have to worry about it or go through any of it. I have daughters and a mom,” she said. “I look forward to the day that we can say this vaccine works.”
Jennifer Davis is a breast cancer survivor and the first person to receive a vaccine that may prevent recurrence of triple-negative breast cancer. The vaccine, developed by Cleveland Clinic and Anixa Biosciences, targets a protein produced by cancer cells and aims to eliminate breast cancer in the future.
- Cathy Cassata
Oct 15, 2019 · Jennifer Davis, stalwart champion of majority rule in South Africa and leader in the anti-apartheid movement in the United States, died on October 15 in Montclair, NJ, surrounded by her family. She was 85.
Browse the list of books by Jennifer Davis, an author of various genres and topics, such as children's books, cookbooks, self-help, and nature guides. See ratings, reviews, and editions for each book.
